Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Brukinsa / zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment as of September 2024

MARA Rating Company December 16, 2025

Upadacitinib for treating moderate rheumatoid arthritis as of November 2021

MARA Rating Company December 16, 2025

Rinvoq / upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs as of February 2022

MARA Rating Company December 16, 2025

Upadacitinib / rinvoq for treating active ankylosing spondylitis as of September 2022

MARA Rating Company December 16, 2025

Upadacitinib / rinvoq for treating moderately to severely active ulcerative colitis as of January 2023

MARA Rating Company December 16, 2025

Rinvoq / upadacitinib for treating active non-radiographic axial spondyloarthritis as of February 2023

MARA Rating Company December 16, 2025

Upadacitinib / rinvoq for treating moderately to severely active Crohn’s disease as of June 2023

MARA Rating Company December 16, 2025

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease as of January 2025

MARA Rating Company December 16, 2025

Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over as of January 2025

MARA Rating Company December 16, 2025

Yondelis / trabectedin for the treatment of advanced soft tissue sarcoma as of February 2021

MARA Rating Company December 16, 2025